To discover actionable vulnerabilities in this refractory breast cancer subtype, we performed a genome-wide CRISPR screen using ER+/RB1-knockout (RBKO) cells and identified protein arginine methyltransferase 5 (PRMT5) as a novel dependency in these cells. Here, RB1 is linked to breast carcinoma.